Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Lulu C Bravo,Josefina C Carlos,Salvacion R Gatchalian,May Emmeline B Montellano, Charissa Fay Corazon B Tabora,Birgit Thierry-Carstensen, Pernille Nyholm Tingskov,Charlotte Sørensen,Henrik Wachmann,Ananda S Bandyopadhyay,Pernille Ingemann Nielsen,Mie Vestergaard Kusk

Vaccine（2020）

引用 9|浏览5

暂无评分

摘要

Non-inferiority of IPV-Al to IPV with respect to seroconversion was confirmed and a robust booster response was demonstrated. Both vaccines had a similar safety profile. ClinicalTrials.gov identifier: NCT03032419.

查看译文

关键词

Affordable IPV,Aluminium hydroxide adjuvant,Booster vaccination,Immunogenicity,Polio,Primary vaccination

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.

Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age.